Subscribe to our newsletter and stay informed

Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.

Eligo Bioscience Secures $30M in Series B Funding to Pioneer Genetic Medicine

Eligo Bioscience, the avant-garde gene-editing powerhouse based in Paris, has clinched a staggering $30 million
December 12, 2023

In the ever-evolving realm of medical science, breakthroughs are occurring at an unprecedented pace. Technologies like CRISPR have ushered in a new era, offering solutions to once-intractable diseases. Eligo Bioscience, a trailblazing gene-editing company based in Paris, is at the forefront of this revolution, having recently closed a remarkable $30 million Series B funding round led by Sanofi Ventures.

The Series B funding round witnessed enthusiastic participation from various key players, including new investor Bpifrance (via its InnoBio 2 fund) and existing supporters Khosla Ventures and Seventure Partners. This financial injection propels Eligo Bioscience into a pivotal phase, fueling the acceleration of its flagship program, EB005.

At the heart of Eligo’s mission is EB005, a groundbreaking program aimed at addressing moderate to severe acne (acne vulgaris), a condition afflicting approximately 3% of the global population. This significant funding surge gears up EB005 for pre-Investigational New Drug [pre-IND] and IND activities, pushing it toward a Phase 1b/2a clinical trial. Beyond acne, Eligo envisions expanding its genetic medicine expertise into other chronic diseases, including oncology.

Eligo Bioscience's innovative approach focuses on the invivo delivery of genetic cargoes to the microbiome, setting it apart from conventional gene therapy and editing. This distinctive strategy broadens the scope of genetic targets that can be effectively addressed, potentially transforming the landscape of chronic and life-threatening diseases influenced by bacterial gene expression.

Sanofi Ventures expressed confidence in Eligo's technology, with Laia Crespo, Ph.D., Partner at Sanofi Ventures, commending the unique delivery and editing technologies developed by Eligo. Xavier Duportet, CEO of Eligo Bioscience, emphasized the strategic importance of this funding, positioning the company to make significant strides in genetic medicine by manipulating the human microbiome.

More about: 

Last related articles

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram